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Abstract
Transplantation of islets in Type 1 diabetes is limited by poor islet engraftment into the liver, with 
2-3 donor pancreases required per recipient. We aimed to condition the liver to enhance islet 
engraftment to improve long-term graft function. Diabetic mice received a non-curative islet 
transplant (n=400 islets) via the hepatic portal vein (HPV) with Fibroblast Growth Factor 7 loaded 
galactoslyated poly(DL-lactide-co-glycolic acid) (FGF7-GAL-PLGA) particles; 26µm diameter 
particles specifically targeted the liver, promoting hepatocyte proliferation in short-term 
experiments: in mice receiving 0.1mg FGF7-GAL-PLGA particles (60ng FGF7) versus vehicle, 
cell proliferation was induced specifically in the liver with greater efficacy and specificity than 
subcutaneous FGF7 (1.25mg/kg ×2 doses; ~75µg FGF7). Numbers of engrafted islets and 
vascularisation were greater in liver sections of mice receiving islets and FGF7-GAL-PLGA 
particles versus mice receiving islets alone, 72 hours post-transplant. More mice (6 out of 8) that 
received islets and FGF7-GAL-PLGA particles normalised blood glucose concentrations by 30-
days post-transplantation, versus 0 of 8 mice receiving islets alone with no evidence of increased 
proliferation of cells within the liver at this stage and normal liver function tests. This work shows 
liver targeted FGF7-GAL-PLGA particles achieve selective FGF7 delivery to the liver promoting 
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1. Introduction
Islets are clusters of polyhormonal cells including insulin secreting β-cells. In Type 1 diabetes 
(T1D), destruction of pancreatic β-cells by autoimmune processes leads to insulin deficiency 
requiring insulin replacement. Severe hypoglycemia (SH) is a side effect of exogenous insulin and 
affects over 10% of those with T1D 1. Human islet allotransplantation stabilizes glycemic control 
and decreases the frequency of recurrent SH in T1D 1-8. However >60% of transplanted islets fail 
to engraft into the liver 9,10 and islets from 2-3 pancreas donors per recipient are needed to impact 
glycemic control 11. Islets are avascular and following islet transplantation, the blood vessel supply 
between islets and the liver starts to form by day 3. The majority of islet loss occurs within the 
first 3 days post-transplant 12. Hypoxia due to a lack of a blood supply and inflammation 
contributes to islet loss 13. We hypothesized that a hepatic microenvironment favouring islet 
retention and vascularisation in the early stages post-transplantation would ameliorate early islet 
loss and aid long-term function.
Preconditioning the host liver with growth factors (GFs) creates a receptive ‘‘niche’’ involving the 
re-modelling and proliferation of liver cells 14,15. Systemic growth factors such as tri-iodothyronine 
(T3) 16,17, hepatocyte growth factor (HGF) 14, and Fibroblast Growth Factor 7 (FGF7) 18 have been 
used to increase rat liver cell proliferation and enhance the efficiency of retroviral gene delivery. 
FGF7 is a small polypeptide member of the FGF family that binds to the FGF7 receptor and has 
proliferative and anti-apoptotic effects on epithelial cells including hepatocytes 18,19. 
GFs may promote islet engraftment through: 1) liver cell proliferation and immediate islet 
“trapping”; 2) up-regulation of VEGF, promoting vasculogenesis and early islet vascularization 
20,21; 3) anti-inflammatory activity, thereby aiding islet survival 22,23; 4) inhibition of T-cell 
mediated immune effects24 reducing islet rejection.
Administering GFs systemically is limited by their short half-life, low tissue penetration, and 
effects on multiple organs. Low GF concentrations in the targeted organ necessitates dose 
escalation with off-target effects 25. We tested targeted GF delivery to the liver to promote 
short-term liver cell proliferation, enhance islet engraftment and improved metabolic control in 
a mouse model of T1D. 
PLGA polymer is a biodegradable material used in medical devices. The polymer matrix achieves 
desirable release kinetics based on the polymer hydration profile 26. For targeted delivery to the 
liver, the PLGA polymer may have galactose added to it, 27,28 exploiting asialoglycoprotein 
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membrane with a specific binding affinity toward the galactose moiety attached on the PLGA 
particles 28. Based upon its ability to induce proliferation in the liver following systemic use, a GF 
was selected for use in an engineered polymer for targeted delivery to the liver. 
Our aim was then to create a microenvironment in the liver suitable for early islet engraftment, by 
using the GF-PLGA polymer associated complex. In order to do this we: 1) characterized the 
biodistribution and release kinetics of several formulations and particle sizes in vivo; 2) identified 
an optimal particle size and dose; 3) co-transplanted GF-loaded galactosylated PLGA (GAL-
PLGA) particles concurrently with a non-curative mass of islets via the clinically relevant hepatic 
portal vein (HPV) into diabetic mice and monitored glycemic control over a 6 week period with 
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2. Materials and Methods
2.1 Animals 
Male C57Bl/6 mice (8-10 weeks old, Harlan Laboratories, UK) were housed under standard 
conditions in a 14-hr light to 10-hr dark cycle and given standard chow and water ad libitum. 
2.2 Injection of growth factors and proliferation of cells within liver
In short-term experiments, twelve week old C57Bl/6 mice (n=8/group) received the following GFs 
or vehicle: Group 1) recombinant FGF7 1.25mg/kg subcutaneously (s.c.) (Sobi Pharmaceuticals, 
Sweden), Group 2) HGF 250μg/kg i.v. (R&D systemsTM, UK), Group 3) T3 4mg/kg s.c. (R&D 
systemsTM, UK), Group 4) all three GFs and Group 5) 100μL saline (vehicle), at day -2 and day 0. 
These doses were based on previous studies 18 with FGF7 which demonstrated that at 24hrs 
following one injection of FGF7 at high dose (5mg/kg), 3 of 8 mice were anorectic and 
hypoglycemic (blood glucose levels between 3.0-3.9 mmol/L) with signs of distress (Suppl. Table 
1). Therefore lower doses of FGF7 were used with no adverse effects. Mice were pulsed with 
BrdU (1mg dissolved in PBS) via intraperitoneal (i.p.) injection 48hrs later and culled 1hr 
afterwards. Liver lobes were processed for immunohistochemistry (see below) with the antibodies 
listed in Suppl. Table 2. The GF associated with the greatest liver cell proliferation was selected 
and given s.c. prior to administering islets via the HPV, to determine if glycemic control was 
improved. This GF was subsequently incorporated into galactosylated PLGA particles.
2.3 FGF7 and effects on insulin secretion and oxygen consumption rates of islets in vitro 
Islets (n=20 islets per well in triplicate) were incubated in 0 (control), 5ng/mL and 30 ng /mL 
FGF7 for 24 hours. FGF7 concentrations were based on concentrations released from 1mg FGF7-
GAL-PLGA particles. Glucose stimulated insulin secretion (GSIS) was measured with insulin 
quantified by ELISA (Mercodia, Sweden) 10 and Oxygen consumption rates (OCR) of islets were 
measured in triplicate as previously described 10.
2.4 PLGA particle preparation, assembly, and characterisation 
PLGA 50:50 lactide:glycolide ratio (52 kDa, DL-lactide, Lakeshore Biomaterials, USA) was 
functionalised with lactobionic acid (LB, Sigma Aldrich, UK) and fabricated from 5.5% PLGA 
in dichloromethane (DCM, Fisher, UK) by a double emulsion method 25. The polymer solution, 
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homogenised stirred, filtered and freeze dried. Particle size distribution (Coulter LS230, 
Beckman, UK) was measured. Protein release (HSA+FGF7) was measured by bicinchoninic 
acid assay (Sigma Aldrich, UK) for 21 days. 
2.5 Biodistribution of particles via the HPV or tail vein 
PLGA particles were rhodamine-labelled. Mice (n=3/group) received an injection of 1 mg PLGA 
particles in 100µL 30% fetal calf serum (FCS). Non-galactosylated PLGA particles (2, 10, 22 µm 
mean diameter) and GAL-PLGA particles (2, 10, 26 µm mean diameter) were injected with a 30G 
needle via the HPV and via the tail vein (i.v.); vehicle injections were also run as controls. Mice 
were culled 24hrs post-injection, blood samples collected by cardiac puncture and the liver, lung, 
kidney, heart and spleen harvested for analysis. 
2.6 Safety and efficacy studies with FGF7-GAL-PLGA particles
Safety and efficacy studies were performed with FGF7-GAL-PLGA particles (26µm) in increasing 
doses. Twelve week old C57Bl/6 mice (6 groups; n= 3-4 / group) received an HPV injection of 
FGF7-GAL-PLGA particles (0.01, 0.1, 1 or 5 mg in 100μL 30% FCS), 30% FCS or FGF7 s.c. 
(1.25 mg/kg; 100µL, once daily for 2 days). Terminal serum samples were collected for LFTs, 
FGF7 and VEGF-A, 72hrs post first injection; livers were processed for immunohistochemistry 
(H+E staining). Liver homogenates were further analysed for VEGF-A concentrations.
Based on the data above, the effect of 26µm FGF7-GAL-PLGA particles (0.1mg) on liver  cell 
proliferation 72 hours post-transplant was determined. C57Bl/6 mice (12 week old; 4 groups; n= 
3-4 per group) were injected via the HPV with: 1) FGF7-GAL-PLGA particles (0.1mg), 2) GAL-
PLGA particles (0.1mg), 3) 30% FCS ×2 (100µL) and 4) FGF7 s.c. (1.25 mg/kg once daily for 2 
days). Mice were pulsed with BrdU 1 mg i.p 1hr pre-cull and livers processed for 
immunohistochemistry (cell proliferation) as described. 
2.7 Mouse islet isolation
Pancreatic islets were isolated from 12 week-old male C57Bl/6 mice by a collagenase digestion 
method 10, islet purity was ≥90%.
2.8 Induction of diabetes in mice
C57Bl/6 mice (n=8-10/group) received streptozotocin (STZ) (Sigma-Aldrich) at 16-17 weeks old 
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were ≥17.0mmol/L (306mg/dL) for two consecutive days. Islet transplantations took place within 
10 days of STZ. 
2.9 Transplantation of islets with subcutaneous FGF7 and FGF7-GAL-PLGA particles
Diabetic C57Bl/6 mice (n=6-8/group) were transplanted with: 1) 400 islets (in 200 µL RPMI 1640 
medium), and 2) 400 islets plus FGF7 1.25 mg/kg s.c. ×2 doses, (48hr pre-transplant and at time 
of transplant). Control experiments included non-diabetic mice (n=4/group) given 3) FGF7 
1.25mg/kg s.c. (100µL) ×2 doses and 4) vehicle (saline (100µL) s.c.×2 doses). Body weight and 
venous blood glucose (OneTouch Verio, LifeScan) were monitored daily and mice sacrificed 6 
weeks post-transplantation. 
Further experiments included diabetic C57Bl/6 mice (n=8-10/group) transplanted with: 1) 400 
islets, 2) 400 islets plus 0.1mg FGF7-GAL-PLGA particles via the HPV, 3) vehicle injected mice. 
Mice were monitored and at 6 weeks post-transplant, mice were fasted overnight given 1mg BrdU 
i.p. and administered a 2g/kg IPGTT with glucose measurements at 15min, 30min, 60min, 90min 
and 120min afterwards and a plasma insulin at 60min. Mice were subsequently culled and livers 
(n=8-10/group) analysed for cell proliferation, vascularization, VEGF-A and fibrosis. Pancreases 
(n=4/group) were analysed for beta cell proliferation. The insulin content of the remaining 
pancreases were extracted and analysed. 
In short-term experiments mice (n=3/group) were transplanted with 0.1mg FGF7-GAL-PLGA 
particles plus 400 islets versus a group transplanted with 400 islets alone (n=3/group) and 
sacrificed 72hr post-transplantation. Livers were analysed using immunohistochemistry for islet 
numbers (insulin and glucagon) and vascularization (CD31 and VEGF-A). 
2.10 Biochemical analysis
ALT, albumin and bilirubin (Alpha Laboratories Ltd., Eastleigh, UK) were analysed on the Cobas 
Fara centrifugal analyser (Roche), human FGF7 and insulin concentrations by ELISA (Thermo 
Scientific, USA; Mercodia, Sweden, respectively); insulin content of the pancreas was measured 
following weighing, homogenisation and sonication 29. VEGF-A was quantified by ELISA in 
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2.11 Histological analysis 
We quantified liver cell proliferation, islet engraftment, liver fibrosis, necrosis and vascularization. 
Tissue was either fixed, embedded in paraffin and cut serially (5µm) or processed using 
cryosections (8-30 µm). In brief to analyse: (i) proliferation-liver sections were immunostained 
with BrdU and hepatocyte nuclear factor 4α (HNF4α) to hepatocyte proliferation and total 
hepatocyte population respectively (ii) PLGA particle detection-rhodamine labelled particles were 
detected using fluorescence microscopy and quantified from an average of eleven ×40 fields per 
organ. To detect rhodamine-labelled PLGA particles in Kupffer cells, the Kupffer cells were 
detected using a rat anti-F4/80 immunostaining followed by an anti-rat Alexa Fluor 488 secondary 
antibody. (iii) islet engraftment-β-cells were quantified in ≥8 formalin fixed paraffin embedded 
(FFPE) sections of liver from all lobes (> 50 µm apart [in Z orientation]). More than 15 non-
overlapping fields per section were evaluated, using ×20 magnification (Nikon Eclipse E600 
fluorescent microscope). The average number of β-cells detected per FFPE section was 
standardized to the total analyzed fields 30. (iv) Necrosis and fibrosis-H&E stains were produced 
using a Shandon Varistain Automated Slide Stainer. Collagen fibres in the liver tissues, were 
detected with picrosirius red (PSR) staining 31. (v) Vascularization- was determined in paraffin-
embedded liver sections using immunofluorescence for CD31 32 and later the ETS-related gene 
(ERG): a transcription factor specific for endothelial cells33; VEGF-A quantification was 
attempted in liver sections using an immunofluorescence method 10,33. For each immunostain, 
control procedures included isotype-matched rabbit monoclonal antibodies. DAPI staining was 
performed to label nuclei. Slides were mounted using an aqueous medium and imaged using an 
Operetta High-Content System (PerkinElmer).
2.12 Statistical Analysis
Results are expressed as mean ±SEM unless otherwise stated. Significance was determined 
by unpaired t tests or one-way ANOVA with Tukey’s post-hoc testing using Prism 6.0 software 
(GraphPad Software, La Jolla, CA). A p <0.05 was considered significant. 
Results 
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FGF7 1.25mg /kg s.c. was associated with the greatest total proliferation of liver cells 
(parenchymal and non-parenchymal) versus HGF 250µg/ kg i.v., T3 4mg/ kg s.c., and all three 
growth factors in combination; all mice were given 2 injections of GFs, the first at the time of 
transplant and the second 48hrs later with liver cell proliferation assessed 48hrs following this 
(Figure 1A). Mice receiving FGF7 s.c. exhibited pronounced cell proliferation in all organs 
including the lungs, pancreas, heart and spleen, as demonstrated by BrdU immunofluorescence 
staining versus controls (Figure 1B and Figure 1C). Therefore, FGF7 was selected for further 
studies. 
3.2 Subcutaneous FGF7 with islets did not control blood glucose levels more effectively than 
transplantation of islets alone 
Mice with diabetes transplanted with 400 islets plus FGF7 1.25mg/kg s.c (×2 injections), did not 
demonstrate improved glycemic control compared with mice transplanted with islets alone by 6 
weeks, with no mice cured from their diabetes: glucose concentrations at 6 weeks: (mean±SEM): 
18.1±2.2 mmol/L vs. 19.2±1.8 mmol/L, respectively (p=0.80). Control normoglycemic mice 
receiving FGF7 (1.25mg s.c. x2 doses) vs. vehicle treated mice showed no difference in glucose 
concentrations over a 6 week period (mean±SEM): 8.6±0.4 mmol/L vs. 8.3±0.6 mmol/L, 
respectively (p=0.91).
3.3 FGF7 has no effect on insulin secretion or OCR in short-term in vitro studies with islets
FGF7 at a dose of 5ng/mL or 30ng/mL had no effect on insulin secretion or OCR (Suppl. Fig. 1). 
3.4 FGF7-GAL-PLGA particles released FGF7 predominantly in the first 48 hours over a 21 
day period
Fabricated GAL-PLGA particles were regular and spherical with porous surfaces (Figure 2A). The 
average diameter of the galactosylated particle was (mean±SD) 26±6 µm with 57±2% FGF7 
loading efficiency (Figure 2B). 
The release kinetics showed an initial burst release phase, releasing ~one-third of the FGF7 
payload on day 1, declining to 8% release on day 2 and 3% on day 3. Release was maintained at 
1% between days 4 to 6 increasing to ~8% release from day 9 to 21 (Figure 2C). Cumulative in 
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weeks (Figure 2D; Table 1). For 0.1mg PLGA particles the FGF7 content was 60ng and a 70% 
release of FGF7 over 21 days was ~40ng FGF7.
3.5 GAL-PLGA particles administered via HPV injection specifically target the liver
Non-galactosylated PLGA particles (mean diameter ~22µm) were found exclusively in lung 
(Figure 3A). In contrast, the galactosylated PLGA (GAL-PLGA) targeted FGF7 delivery to the 
liver; 26µm diameter particles conferred exclusive hepatic localisation. Smaller GAL-PLGA 
particles (~2µm and 10µm diameters) showed hepatic retention but not exclusively (Figure 3A-C). 
The smallest GAL-PLGA particles (diameter ~2µm), were engulfed by F4/80-positive liver 
resident macrophages (Figure 3D). In parallel, the biodistribution of PLGA-particles after 
injection into a tail vein was determined. A large proportion of the GAL-PLGA-particles (10µm 
diameter) were retained in the lung. Therefore larger sizes (26µm diameter) of GAL-PLGA 
particles were not tested for hepatic localisation as it was reasoned that these too would be trapped 
in the lung (Suppl. Fig 2A-C).
 
3.6 A FGF7-GAL-PLGA particle dose of 0.1mg injected via the HPV was associated with a 
stable body weight and normal liver function tests 
Mice receiving 0.01mg and 0.1mg FGF7-GAL-PLGA particles via the HPV remained well with 
no demonstrable weight loss and no difference in serum albumin (marker of hepatocyte function), 
ALT or bilirubin (markers of liver injury) at 72hrs after transplant versus vehicle (Fig. 4A-C), an 
effect that was still apparent 6 weeks post-transplant (Suppl. Fig. 3). Human FGF7 serum levels 
were detected at 24hrs in mice transplanted with 0.1mg FGF7-GAL-PLGA particles (Fig. 4D). In 
the group administered 0.1mg FGF7-GAL-PLGA particles blood vessels in the liver appeared 
macroscopically milky white 24 hours after injection via the HPV and H&E staining exhibited 
occasional small necrotic areas (Fig. 4E and Fig. 4F). 
Higher doses of FGF7-GAL-PLGA particles (1mg and 5mg) were not associated with significant 
weight loss 24 hours post injection (Suppl. Fig. 4A) but an increase in liver injury markers 
including ALT, bilirubin and albumin was observed (Suppl. Fig. 4B-D) with patchy liver necrosis 
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3.7 FGF7-GAL-PLGA particles (0.1mg) significantly increased proliferation of liver cells at 
72 hours post-transplant with no increased proliferation at 6 weeks post-transplant
Based on the dose response studies, 0.1mg PLGA-GAL-FGF7 particles were administered via the 
HPV in mice and liver cell proliferation (total and hepatocyte) examined at 72hrs. Co-localisation 
of BrdU+ and HNF4α+ cells in liver sections of mice that received FGF7-GAL-PLGA particles 
(Fig. 5A) was 1.5-fold greater than in mice receiving FGF7 1.25mg/kg s.c. ×1 dose per day for 2 
days. The greatest cell proliferation overall was observed in the liver of mice treated with FGF7-
GAL-PLGA particles (Fig. 5B, proportion (%) of proliferating cells in the liver (1.7±0.1% vs. 
0.9±0.1% in mice received FGF7 s.c.; p=0.03) and 55 % of proliferating cells were hepatocytes 
(p=0.04, Fig. 5C). 
At 6 weeks, the % proliferating cells in the liver of mice treated with FGF7-GAL-PLGA particles 
was not significantly different vs. control hyperglycemic mice: (0.009 ± 0.002 % vs. 0.015±0.001 
%; n=4, p=0.13).
 3.8 FGF7-GAL-PLGA particles (0.1mg) transplanted with islets promoted early islet 
engraftment with improved long-term glycemic control with no evidence of liver fibrosis
Greater numbers of islets were seen in the livers of hyperglycemic mice transplanted intraportally 
with islets and FGF7-GAL-PLGA particles vs islets alone as evidenced by greater numbers of dual 
insulin-glucagon positive cells in the liver 72hrs post-transplant (Fig. 6A and Fig. 6B, p=0.02). At 
72hrs post-transplant, the percentage area of liver that was CD31 positive was greatest in mice 
treated with FGF7-GAL-PLGA particles (0.1mg) plus islets vs. islets alone and vs. GAL-PLGA 
particles alone: 6.8±0.9% versus 5.6±0.6% versus 2.2±0.06% (p=0.04; Fig 7A and 7B). At 6 
weeks ERG and CD31+ staining was non-significantly greatest in the livers of mice co-
transplanted with FGF7 particles with islets (Fig. 7C and Fig. 7D, p=0.12). There was no VEGF-A 
staining in the livers quantifiable over the background compared to the isotype control in mice at 
72hr and 6 weeks post-transplant (Suppl. Fig 5A and 5B). VEGF-A concentrations were 
detectable in serum and liver homogenates at 72hr and 6 weeks post-transplant with non-
significantly greater concentrations in mice transplanted with 5mg FGF7 particles (Suppl. Fig 5C 
and D). 
Mice receiving islets and FGF7-GAL-PLGA particles had tighter glycemic control vs. those 
receiving islets alone with blood glucose levels normalising by day 30 post-transplant (Fig. 8A, 
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Stimulated insulin concentrations at 60min post i.p.GTT were not significantly different between 
the islet alone versus islet+FGF7-GAL-PLGA groups: (median(IQR)): 150(143-170) vs. 155(148-
182) pmol/L, p=0.37. When glucose concentrations were expressed in relation to insulin 
concentrations at 60mins post 2g/kg i.p.GTT, however, mice co-transplanted with FGF7 had 
greater insulin:glucose ratios (Fig 8B).
There was no difference in collagen content in the liver tissues between the groups at day 42 (Fig. 
8C-D). Serum biomarkers for liver injury at 6 weeks post-transplant were not different to controls 
(Suppl. Fig. 4A-C).
3.9 No evidence of pancreas regeneration 6 weeks post-transplantation of islets ± 
galactosylated FGF7-GAL-PLGA particles (0.1mg)
No proliferating ß-cells were detected in the pancreases of mice treated with FGF7-GAL-PLGA 
particles (Suppl. Fig 6A). There was no significant difference in pancreatic insulin content 
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4. Discussion
Transplantation of islets into patients with T1D stabilizes glycemic control, reducing SH 1,5,34 but 
due to poor engraftment of islets into the liver 35,36 islets from 2 to 3 donor pancreases, a scarce 
resource, are required. 
In diabetic rodents, partial hepatectomy preceding intra-portal islet transplantation is associated 
with improved glycemic outcomes versus islet transplant alone, likely due to GF release, 
remodelling of the liver niche and liver cell proliferation, improving islet engraftment and 
revascularization 20,30,37. However, partial hepatectomy is not a clinically applicable adjuvant 
therapy for intraportal islet transplantation in man. FGF7 RNA is expressed in most organs 
throughout the human body, with moderate expression in the pancreas and no expression in the 
islet in adulthood 38. FGFR2 is the cognate receptor for FGF7 and has been localised to the beta 
cells of the islets of Langerhans 39 but is absent from the alpha cells and the exocrine pancreas 40. 
Islets are mainly derived from the cells of the bud epithelium and FGF7 treatment activates ductal 
cell proliferation and their subsequent differentiation into β-cells in human fetal pancreatic cell 
preparations 41. In an adult islet however exogenous FGF7 causes the ductal epithelium to 
proliferate but there is no evidence of endocrine differentiation or β-cell proliferation 42. In our 
experiment with adult mouse donor islets, it is unlikely that adult intra-islet ductal cells 
differentiated into β-cells. 
In our studies FGF7 promoted proliferation of cells within the liver and it seems likely that this is 
one of the dominant mechanism promoting islet engraftment within the liver. 
Of note the doses of growth factors used were based on safety and efficacy from our own 
experiments and the published literature and were not administered in equimolar amounts. The 
combination of FGF7, HGF and T3 was less efficacious with respect to proliferation of liver cells 
versus FGF7 alone. We hypothesize that there is a balance between metabolic demand of the 
tissue and proliferation of cells in the liver–with all three GFs metabolic demand may be greater 
than with FGF7 alone impacting negatively on proliferation of liver cells.
Our results demonstrate increased vascularization of islets in the liver, with increased endothelial 
marker staining (CD31) in the liver at an early stage, coupled with improved glycemic control 
when the liver is targeted by FGF7 contained in galactosylated PLGA particles: the numbers of 
islets in the liver were greater in the mice receiving a portal injection of 0.1mg PLGA-GAL-FGF7 
particles of 26µm diameter plus islets versus those receiving islets alone. Importantly the dose of 
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fold lower dose than the dose of 1.25mg/kg FGF7 (×2 doses) administered subcutaneously to 
mice.
Furthermore, the majority of mice administered these particles were cured following islet 
transplantation. Importantly, there was no β-cell regeneration in the native pancreas and FGF7 did 
not augment insulin secretion in our in vitro experiments, consistent with the beneficial effects 
being mediated by improved hepatic islet engraftment. Of note, there was no evidence of 
diminished OCRs from islets exposed to FGF7 and therefore no evidence of an adverse effect of 
FGF7 on islet function in the short-term. Subcutaneous FGF7 increased hepatic non-parenchymal 
cell proliferation, however glycemic control was not improved following islet transplantation. 
FGF7 was not detectable systemically 24hrs following subcutaneous administration and these 
short-term effects may not be sufficient to increase islet engraftment. Islet engraftment, where 
blood vessels form between the islets and the liver, occurs largely between days 3 to 28 43. 
Subcutaneous FGF7 also causes cell proliferation in other organs including the lungs, pancreas, 
kidney, heart and spleen which limits clinical applicability.
When GAL-PLGA particles were studied over a 21 day period, the route of administration, 
particle size and galactosylation influenced its sequestration within organs. The 26µm GAL-
PLGA particles delivered via the HPV route were sequestered solely in the liver. Smaller 
galactosylated particles (2µm and 10µm) delivered via the HPV route, were sequestered in the 
liver and the capillary beds of the lungs, spleen and other organs. Control PLGA particles of 22µm 
without the galactosylated moiety were sequestered in the lung only, demonstrating that 
galactosylation is required for localisation of the particle in the liver via ASGPR-mediated 
endocytosis. When the 10µm GAL-PLGA particles were delivered peripherally, a large proportion 
were trapped in the lung with only some reaching the liver; hence this would not be a feasible way 
to translate this therapy into man.
In our short-term experiments, FGF7 60ng packaged into 0.1mg PLGA particles caused liver 
proliferation with no change in liver serum markers although a minute patch of necrosis was seen 
which requires further exploration. With this dose of FGF7, 55% of proliferating cells were 
hepatocytes, contrasting with 22% when two doses of 1.25mg/kg FGF7 were administered 
subcutaneously. Liver injury including patchy necrosis of the liver was demonstrable with 1mg 
and 5mg FGF7-GAL-PLGA particles, suggesting dose response studies in larger animal models 
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was no evidence of hepatocyte proliferation, suggesting that modulation of the liver niche in the 
short-term is sufficient for islet engraftment with no long-term deleterious effects in the liver.
Numbers of islets transplanted 44, along with younger donor age 45 impact transplant outcome. 
This study demonstrates that modulation of the liver niche by FGF7-GAL-PLGA particles is a 
potential therapeutic strategy for increasing islet engraftment and islet transplant outcomes in man. 
FGF7 may increase engraftment of islets by stimulating angiogenesis via VEGF induction directly 
21 or indirectly 46,47 in keeping with increased hepatic CD31 staining at 72hrs post transplant in 
recipient mice. We did not detect VEGF-A in liver, the immunoflouresence technique may not be 
sensitive enough to detect VEGF-A at low levels or it may be upregulated at a different time point. 
In this study 0.1mg of FGF7-GAL-PLGA particles would release ~40ng of FGF7 in a mouse over 
21 days leading to increased islet engraftment in the liver. FGF7 has FDA approval and held a 
license for severe oral mucositis in patients with hematologic malignancies receiving myelotoxic 
therapy. The recommended dose is ~25mg intravenously for a 70kg person over a 6 day period 48. 
Extrapolating the dose of FGF7 administered in a mouse via particles direct to the liver to humans 
on a weight for weight basis, the dose used in man via the HPV would be >250 fold lower than the 
licensed dose for treating oral mucositis. We believe this treatment can potentially be translated 
into man. Such a strategy would mean that islets isolated from just one donor pancreas may be 
sufficient to diminish hypoglycemia and stabilize glycemic control in patients with T1D enabling 
more patients to be transplanted.
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Figure Legends
Figure 1
Cell proliferation in liver and other organs after injection of GFs. Mice received ×2 injections 
of the following GFs or vehicle 48 hours apart (day 0 at Transplant and day 2) and culled 48 hours 
following the last injection of growth factor or vehicle. One hour before cull, BrdU was injected 
i.p. to detect cell proliferation. The number of BrdU positive cells (=proliferating cells) was 
evaluated by the Operetta system and Columbus software. 
 (A) vehicle (100 μL saline) s.c., HGF 250 μg/kg i.v., T3 4 mg/kg s.c., FGF7 1.25 mg/kg s.c, or 
combination of all three GFs. (B) Immunofluorescence staining for BrdU in various organs in 
mice receiving FGF7 1.25 mg/kg s.c. ×2 doses or (C) vehicle 100 μL saline s.c ×2 doses. 
Arrows indicate BrdU positive cells. DAPI (blue) indicate cell nuclei. Data represent the mean ± 
SEM.
Figure 2
Characterisation of GAL-PLGA particles. (A) Representative scanning electron micrographs of 
particles. (B) Size distribution of particles with average size diameter and entrapment efficiency 
(%) for total protein. (C) Individual daily release percentage, and (D) Cumulative release kinetics 
for the total protein payload over a three week period. Data represent mean±SD. EE – entrapment 
efficiency. 
Figure 3
Hepatic portal vein injection of 26 μm GAL-PLGA particles via the HPV provides specific 
hepatic localisation. PLGA particles non-galactosylated (22µm) and GAL-PLGA (2, 10 and 
26µm) were injected into mice (1mg, HPV) to determine particle distribution in organs. (A) 
Representative fluorescent images (×40) of organs extracted 24 hours after injection of particle 
formulations. Cryosections (30µm) were fixed and stained: DAPI (blue, cell nuclei); fluorescent 
particles (red epifluorescence) are highlighted (white arrows). (B) Mean particle counts 
(logarithm, from 11 slides) quantified per tissue grouped in formulations indicated. Bars represent 
the mean ± SD, n=3 mice per group. (C) Percentage of GAL-PLGA (26 µm) and non-
galactosylated (22µm) PLGA-particle biodistribution in various organs. (D) Small particles (2 µm, 
white arrows) localise with F4/80 positive cells (green) in liver tissue suggesting phagocytic 
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Figure 4
Dose response study shows that particles do not cause overt hepatotoxicity
(A) Serum ALT activity, (B) albumin (C) bilirubin and (D) human FGF7 levels from mice 
transplanted via HPV receiving FGF7-GAL-PLGA particles (26 μm; 0.01mg and 0.1mg) versus 
vehicle (30%, 100 μL FCS); additional groups in D mice receiving FGF7 s.c. 1.25mg/kg s.c. ×2 
doses. (E) Macroscopic view of the liver pre- and post-transplant with FGF7-GAL-PLGA 
particles  (F) H-E staining liver (the black arrow indicates a necrotic patch). Mice were culled 
72hrs post-transplant. 
Data are mean ± SEM, n=3 mice per group. HPV: hepatic portal vein. 
Figure 5
Effects of targeted FGF7-GAL-PLGA delivery via HPV versus FGF7 s.c. on liver cell 
proliferation. (A) FGF7 1.25 mg/kg s.c. ×2 doses, 0.1 mg FGF7-GAL-PLGA (HPV) or 
GALPLGA alone (HPV), 30% FCS (HPV), 72hr following first injection. BrdU was administered 
1mg i.p before cull. Representative micrographs of dual immunostaining applied on liver sections 
for BrdU (green, cell proliferation), HNF4α (red, hepatocytes) and DAPI (blue, nucleus staining). 
In the upper panels, white arrows show BrdU+ non-parenchymal cells (HNF4α -), as magnified in 
the inset. In the middle row, mainly dual positive nuclei are observed (orange-yellow), while in the 
lower panel (PLGA alone treated mice), the proliferating cells were mainly non-parenchymal. 
Inset (×400) show higher magnified regions of liver sections of different treatments. (B) 
Percentage of the proliferating (BrdU+) cells in each mouse group. (C) Fraction of proliferating 
hepatocytes (BrdU+, HNF4α +) to the total proliferating cells (BrdU+). 
Cell counting by Operetta system and Columbus. Scale 100 μm. * P<0.05 using one-way ANOVA 
Tukey’s post-hoc. 
Figure 6
Islet detection in liver tissue 72hrs post islet-transplantation. Intraportal islet transplants islets 
alone (n=400), and islets (n=400) co-transplanted with FGF7-GAL-PLGA particles (0.1mg) were 
performed and mice (n=3 per group) culled 72hrs post-transplant. (A) Dual immunofluorescence 
staining for islets (insulin- β cells and glucagon- α cells) in liver tissues. Scale 100 μm. (Note - 
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(B) Average area of β-cells from ≥ 8 FFPE sections from all 4 lobes of the liver were quantified 
from ≥ 15 non-overlapping fields and expressed in terms of graft area (%). Each data point 
represents the average β-cell to total graft area from 120 fields under 20X magnification. Mean ± 
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Figure 7
CD31 detection at 72hrs and ERG detection at 6 weeks post-transplant in whole liver 
sections
At 72hrs post-transplant groups of mice were studied (n=4/gp): 1) vehicle –hyperglycemic, 2) 
intraportal islet transplants alone (n=400); 3) islets (n=400) co-transplanted with FGF7-GAL-
PLGA particles (26um diameter, 0.1mg).
(A) Immunofluorescence staining for CD31 nuclei in liver tissues. (B) Quantification of CD31 
nuclei in groups. p=0.04; one-way ANOVA.
At 6 weeks post-transplant three groups of mice were studied (n=5-8/gp): hyperglycemic-vehicle, 
intraportal islet transplants alone (n=400), and islets (n=400) co-transplanted with FGF7-GAL-
PLGA particles (26um diameter, 0.1mg). (A) Immunofluorescence staining for ERG nuclei in 
liver tissues. (B) Quantification of ERG nuclei in all groups. p=0.12 ; one-way ANOVA.
Figure 8
Biochemical assays and assessment of liver fibrosis in diabetic C57Bl/6 mice transplanted 
with a marginal islet mass ± FGF7-GAL-PLGA particles (0.1mg) monitored for 6 weeks. (A) 
Non-curative mass intraportal islet transplantation ± FGF7-GAL-PLGA particles (0.1mg). Daily 
blood glucose concentrations are shown. Islets alone vs. islets + FGF7-GAL-PLGA (0.1mg) 
particles * P=0.03 one-way ANOVA. (B) Insulin:glucose ratio was significantly increased in the 
islet+FGF7-GAL-PLGA group. (C) Picrosirius red (PSR)-stained liver tissues for fibrosis, (D) 
Percentage of collagen (red pixels) to liver tissue (yellow). Each value represents the mean of 8 
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Tables 
Table 1 Release of FGF7 (% and ng/ 1mg particle) at the selected time points up to day 21 
Day Release (%) Release in ng per 1mg particles
1 28.4 (±2.1) 163.3 (±5.5)
2 7.8 (±1.3) 45.4 (±9.5)
3 2.5 (±1.5) 14.5 (±1.5)
4 1.6 (±0.2) 9.3 (±2.0)
5 1.3 (±0.07) 7.9 (±0.7)
6 1.1 (±0.2) 6.8 (±1.4)
7 1.3 (±0.1) 7.7 (±0.9)
9 3.0 (±0.7) 17.5 (±4.9)
11 3.1 (±0.1) 18.0 (±1.7)
13 2.9 (±0.06) 16.9 (±0.7)
17 5.9 (±0.9) 33.9 (±4.0)
21 7.2 (±2.0) 44.7 (±9.7)
Microparticles (FGF-GAL-PLGA - 25 mg) were set up in triplicate and suspended in 1 ml PBS, 
gently rocked on a 3-dimensional shaker (Gyrotwister, Fisher Scientific UK Ltd) at 5 rpm in a 
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